| Metric | Q4 FY26 | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue from operations | 939649419.4 | 872675344.7 | 937636740.7 |
| Other income | 28942990.5 | 23096689.9 | 39620995.3 |
| Total income | 968592409.9 | 895772034.5 | 977257736.0 |
| Profit before exceptional items & tax | 118314215.7 | 104720375.0 | 144554097.2 |
| Exceptional items | 0.0 | 0.0 | 22222844.0 |
| Profit before tax | 118314215.7 | 104720375.0 | 122331253.2 |
| Net profit | 90489234.0 | 85172567.3 | 90344028.2 |
| Operating margin | 12.2% | 11.7% | 12.5% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +0.20% |
|---|---|
| Net profit, quarter on quarter | +6.20% |
| Revenue, year on year | +0.20% |
NSE results filing, NSE: BETA. Figures extracted from the filing.
Beta Drugs Ltd: key numbers
- Share price
- ₹2,098.70
- Market cap
- ₹2,327 Cr
- Revenue (annual)
- ₹384.8 Cr
- Net profit (annual)
- ₹41.48 Cr
- P/E (TTM)
- 51.0×Sector 50.4×
- Promoter holding
- 59.10%-5.53% QoQ
- FII holding
- 1.02%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Beta Drugs Ltd
All →Beta Drugs Business Update
Beta Drugs secured Azerbaijani regulatory approvals for its oncology portfolio across multiple dosage forms. The company targets Azerbaijan commercialisation during the current financial year.
Beta Drugs Annual General Meeting
Beta Drugs Limited has scheduled its 21st Annual General Meeting for September 30, 2026, at its registered office in Baddi, Himachal Pradesh.
Beta Drugs Management Change
Beta Drugs Limited announced the re-appointment of its Statutory Auditor and an Executive Director. These re-appointments are effective from September 2026 and January 2027, respectively.
Beta Drugs Board Meeting Outcome
Beta Drugs Limited announced its board meeting outcome, covering AGM arrangements, auditor appointments, and the re-appointment of its Whole-Time Director, Ashutosh Shukla.
Beta Drugs Investor Presentation: Key Takeaways
Beta Drugs Ltd. reports Q1-FY27 revenue of INR 1,255 Mn with 21.83% EBITDA margin. Diversifying beyond core oncology into IVF via Nivian acquisition.
- Call
- Guides 15% growth
Beta Drugs Earnings Call: Key Takeaways
Beta Drugs delivered record EBITDA but missed revenue guidance due to delayed export tenders and strategic withdrawal from the low-margin Platin segment.